All In Biotech

Drug Trial Radar · NCT05751642

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1920 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Apr 19, 2023

Primary completion

Dec 4, 2023

Study completion Dec 4, 2023

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1920 subcutaneous (SC) and of a single dose of ALXN1920 intravenous (IV) in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • ALXN1920Biological

    Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.

  • PlaceboBiological

    Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.

  • ALXN1920Biological

    Participants will receive a single dose of ALXN1920 by SC infusion.

  • ALXN1920Biological

    Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse events (AEs)Time frame: Up to End of study visit (Day 29)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Christchurch, New Zealand

  • Clinical Trial Site

    Grafton, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.